1. Home
  2. UG vs CTSO Comparison

UG vs CTSO Comparison

Compare UG & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UG
  • CTSO
  • Stock Information
  • Founded
  • UG 1942
  • CTSO 1997
  • Country
  • UG United States
  • CTSO United States
  • Employees
  • UG N/A
  • CTSO N/A
  • Industry
  • UG Package Goods/Cosmetics
  • CTSO Medical/Dental Instruments
  • Sector
  • UG Consumer Discretionary
  • CTSO Health Care
  • Exchange
  • UG Nasdaq
  • CTSO Nasdaq
  • Market Cap
  • UG 36.8M
  • CTSO 68.2M
  • IPO Year
  • UG N/A
  • CTSO N/A
  • Fundamental
  • Price
  • UG $8.03
  • CTSO $0.87
  • Analyst Decision
  • UG
  • CTSO Strong Buy
  • Analyst Count
  • UG 0
  • CTSO 3
  • Target Price
  • UG N/A
  • CTSO $4.67
  • AVG Volume (30 Days)
  • UG 12.8K
  • CTSO 138.7K
  • Earning Date
  • UG 05-08-2025
  • CTSO 05-14-2025
  • Dividend Yield
  • UG 8.72%
  • CTSO N/A
  • EPS Growth
  • UG 4.82
  • CTSO N/A
  • EPS
  • UG 0.63
  • CTSO N/A
  • Revenue
  • UG $11,408,154.00
  • CTSO $35,594,520.00
  • Revenue This Year
  • UG N/A
  • CTSO $18.72
  • Revenue Next Year
  • UG N/A
  • CTSO $19.75
  • P/E Ratio
  • UG $11.28
  • CTSO N/A
  • Revenue Growth
  • UG N/A
  • CTSO 14.51
  • 52 Week Low
  • UG $7.73
  • CTSO $0.70
  • 52 Week High
  • UG $16.25
  • CTSO $1.61
  • Technical
  • Relative Strength Index (RSI)
  • UG 41.60
  • CTSO 33.89
  • Support Level
  • UG $7.85
  • CTSO $0.87
  • Resistance Level
  • UG $8.44
  • CTSO $1.16
  • Average True Range (ATR)
  • UG 0.39
  • CTSO 0.07
  • MACD
  • UG 0.03
  • CTSO -0.02
  • Stochastic Oscillator
  • UG 22.14
  • CTSO 0.00

About UG United-Guardian Inc.

United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: